CLINICAL RESEARCH - DOCTORS NEW TO CANNABIS BASED MEDICINE
Cannabis Clinical Research Reports for Medical Doctors
Now that medical marijuana is legal in most parts of the United States, more medical doctors are beginning to take a serious look at it to treat their patients. Since the Federal Government forced cannabis based medicines to be removed from US Pharmacopeia back in the 1930's (when it was legal and prescribed), the medical establishment, until very recently has provided doctors with basically no information about cannabis based medicines.
However, medical research into the efficacy of cannabis in medicine is booming in some of the best research institutes and universities. Some of the most recent profound clinical findings are presented here.
GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol Acta Pharmacol Sin. 2018 June 25.
Discovery highlights these orphan receptors as potential new molecular targets for CBD, provides novel mechanisms of action, and suggests new therapeutic uses of CBD for illnesses such as Alzheimer's disease, Parkinson's disease, cancer, and infertility. Furthermore, identification of CBD as a new inverse agonist for GPR3, GPR6, and GPR12 provides the initial chemical scaffolds upon that potent and efficacious agents acting on these receptors can be developed, with the goal of developing chemical tools for researching these orphan receptors and ultimately new therapeutic agents.
Is Cannabidiol a Promising Substance for New Drug Development? A Review of its Potential Therapeutic Applications. Crit Rev Eukaryot Gene Expr. 2018;
Potential therapeutic applications of CBD include, analgesic, anti-inflammatory, anxiolytic, anti-arthritic, anti-depressant, anti-Alzheimer disease, anti-ischemic, neuroprotective, and anti-fibrotic. Much more promising areas might to include diabetes and cancer where CBD exhibits lesser side effects and more therapeutic benefits as compared to recent available medical therapies.Therefore, CBD is a promising substance for the development of novel drug. However further research and clinical studies are needed to explore its complete potential.
The target dose for relieving pain in medical patients with malignant conditions is most likely approximately 10 actuations per day, that is approximately 27 milligram tetrahydrocannabinol (d9THC) and 25 milligram cannabidiol (CBD), and the greatest endorsed recommended dose is 12 actuations per day (32 milligram d9THC/30 milligram CBD). Further large studies of phytocannabinoids from marijuana in homogeneous populations are needed.
Our group present an actual state of medical knowledge regarding molecular mechanisms of phytocannabinoids from marijuana' anticancer action, but our group discuss also aspects that are still not fully understood such as the role of the body's own cannabinoid system in a carcinogenesis, the efficacy of phytocannabinoids from marijuana on the immune system in the setting of cancer development, or the cases of a stimulation of cancer cells' proliferation by phytocannabinoids from marijuana. The review includes also a summary of the latest ongoing clinical trials evaluating the safety and efficacy of phytocannabinoids from marijuana as anticancer agents.
Cannabinoid-induced cell death in endometrial cancer cells: involvement of TRPV1 receptors in apoptosis. J Physiol Biochem. 2018 May;7
These clinical data shows that phytocannabinoids from marijuana modulate endometrial cancer cell death. Selective targeting of TRPV1 by AEA, CBD, or another stable analogues may be an attractive research area for the treatment of estrogen-dependent endometrial carcinoma. Our clinical data further back up the inspection of CBD and CBD-rich concentrated extracts for the potential treatment of endometrial cancer, particularly, that has become non-responsive to common therapies.
Psychotropic phytocannabinoids from marijuana from marijuana exert multiple pharmacological effects with therapeutic potential in many conditions such as inflammation, cancer, diabetes. Here, it is have investigated the inhibitory effects of concentrated extracts and their fractions from two Cannabis sativa L. chemotypes with high content of cannabidiol (CBD)/cannabidiolic acid (CBDA) and cannabigerol (CBG)/cannabigerolic acid (CBGA), respectively, on human recombinant and bovine kidney aldose reductase activity in vitro. A molecular docking study was performed to evaluate the interaction of these phytocannabinoids from marijuana with the active site of ALR2 compared to known ARIs.
The concentrated extracts showed significant dose-dependent aldose reductase inhibitory activity (>70%) and higher than fractions. The inhibitory activity of the fractions was greater for acidic cannabinoid-rich fractions. Comparative molecular docking results have shown a higher stability of the ALR2-cannabinoid acids complex than the other inhibitors. The concentrated extracts of marijuana with high content of non-psychotropic phytocannabinoids from marijuana CBD/CBDA or CBG/CBGA significantly inhibit aldose reductase activity. These results may have some relevance for the possible use of C. sativa chemotypes based preparations as aldose reductase inhibitors.
In this study the distribution and density of various types of Cannabis sativa L. trichomes, have been investigated by scanning electron microscopy.
The hereby documented detection of metabolites in the stems of capitate-stalked trichomes indicates a complex biosynthesis and localization over the trichome cells forming the glandular secretion unit.
Glandular trichomes were isolated over the flowering period (8 weeks) by laser microdissection and the cannabinoid profile analyzed by LCMS.
Trichomes, especially the capitate-stalked glandular hairs, are well known as the main sites of cannabinoid and essential oil production of Cannabis sativa.
Cannabichromene along with cannabinol were identified as minor compounds only in the samples of intact capitate-stalked trichomes and their heads harvested from 8-week old plants.
Cannabinoids were detected in extracts of 25-143 collected cells of capitate-sessile and capitate stalked trichomes and separately in the gland and the stem of the latter. d9-Tetrahydrocannabinolic acid cannabidiolic acid, and cannabigerolic acid were identified as most-abundant compounds in all analyzed samples.
Their decarboxylated derivatives, d9-tetrahydrocannabinol, cannabidiol, and cannabigerol , co-detected in all samples, were present at significantly lower levels.
Cryogenic NMR enabled the additional identification of cannabichromenic acid in the dissected trichomes, which was not possible by LCMS as standard was not available.
Cryogenic nuclear magnetic resonance spectroscopy was used to confirm the occurrence of major cannabinoids, THCA and CBDA , in capitate-stalked and capitate-sessile trichomes.
These results are relevant to the analgesic, anti-inflammatory and anti-cancer effects of cannabinoids and Cannabis extracts.
All non-acid cannabinoids, except CBC and CBN, potently activated and desensitized rat TRPV2. CBDV and all the acids inhibited DAGLα. Some BDS, but not the pure compounds, inhibited MAGL.
CBD, CBG, CBGV and THCV stimulated and desensitized human TRPV1. CBC, CBD and CBN were potent rat TRPA1 agonists and desensitizers.
CBD was the only compound to inhibit FAAH, whereas the BDS of CBC greater than CBG greater than CBGV inhibited NAAA. CBC equals CBG greater than CBD inhibited ACU, as did the BDS of THCVA, CBGV, CBDA and THCA, but the latter extracts were more potent inhibitors
THCV-BDS was the most potent compound at this target. CBG-BDS and THCV-BDS were the most potent rat TRPM8 antagonists.
420EVALUATIONSONLINE - Our medical doctor's can process your online application for a California Medical Marijuana Card and Recommendation. New and old patients can apply. Your medical marijuana card allows for the purchase of concentrates and the strongest strains at lower prices, with full access to products that are not allowed to recreational users in some counties and cities. Medical patients can grow many more plants, in practice up to 24 (depends on your condition and cannabis requirements). Savings on cannabis purchases can be $20,$30,$40 dollars per ounce and when insurance companies start to allow cannabis on their plans, it will be for established and approved medical marijuana users.